Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Section Content Menu
Skip to Common Links
Enter Search terms
A-Z Index
Home
Food
Drugs
Medical Devices
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Radiation-Emitting Products
Tobacco Products
-
Drugs
Home
>
Drugs
>
Guidance, Compliance & Regulatory Information
>
Guidances (Drugs)
Section Contents Menu
Guidance, Compliance & Regulatory Information
Guidances (Drugs)
Advertising
Biopharmaceutics
CMC - Microbiology (Chemistry, Manufacturing, and Controls)
Chemistry, Manufacturing, and Controls (CMC)
Clinical / Antimicrobial
Clinical / Medical
Clinical Pharmacology
Combination Products
Concept Papers
Current Good Manufacturing Practices (CGMPs)/Compliance
Drug Safety
Electronic Submissions
FDAAA (Food and Drug Administration Amendments Act)
Generics
Good Review Practices
Individual Product Bioequivalence Recommendations
Industry Letters
International Conference on Harmonisation - Efficacy
International Conference on Harmonisation - Joint Safety/Efficacy (Multidisciplinary)
International Conference on Harmonisation - Quality
International Conference on Harmonisation - Safety
Investigational New Drug Applications
Labeling
Microbiology
Modernization Act
Over-the-Counter
Pharm / Tox
Procedural
Small Entity Compliance Guides
User Fees
-
Drug Safety
Title and Format
Type
Issue Date
Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review (PDF - 1516 KB)
Final
2/2005
Drug-Induced Liver Injury: Premarketing Clinical Evaluation (PDF - 206 KB)
Final
7/29/2009
Drug Safety Information - FDA's Communication to the Public (PDF - 114 KB)
Final
3/2/2007
Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS),
REMS Assessments, and Proposed REMS Modifications (PDF - 316 KB)
Draft
9/30/2009
Postmarketing Studies and Clinical Trials — Implementation of
Section 505(o) of the Federal Food, Drug, and Cosmetic Act (PDF - 173 KB)
Draft
7/15/2009
-
-
Share
Email this Page